Seirafi Hassan; Ehsani Amirhooshang; Jesri Shabboo; Gholamali Fatemeh; Noormohammadpour Pedram
Volume 15, Issue 4 , 2012, , Pages 117-121
Abstract
Background: Infantile hemangioma is a congenital vascularmalformation. Although almost all cases are self-limiting, treatmentis sometimes necessary. According to previous studies, topicalimiquimod induces resolution of lesions with an acceptable safetyprofile. The aim of the present study was to evaluate ...
Read More
Background: Infantile hemangioma is a congenital vascularmalformation. Although almost all cases are self-limiting, treatmentis sometimes necessary. According to previous studies, topicalimiquimod induces resolution of lesions with an acceptable safetyprofile. The aim of the present study was to evaluate the effect ofthis topical treatment on Iranian infantile hemangioma patients.Method: Patients under two years of age with infantile hemangiomawho were not candidates for immediate systemic therapy withsteroids were selected if the lesions were not ulcerated. Topical5% imiquimod was applied on the lesions for 16 weeks. All thelesions were photographed before the commencement of the studyand at the end of the treatment. Photographs were compared bytwo associate dermatology professors to evaluate the effect oftreatment using a visual analogue scale.Result: A total of 15 patients including five males (33.3%) andten females (66.7%), with an age range of two to 18 months anda mean age of 9.1 (± 6.3) months, were enrolled in the study.The mean diameter of the lesions was 2.6 cm (± 1.8 cm). Ninepatients (60%) had moderate response and five patients (33.3%)had good response while one patient had excellent response.Complications were mild local irritation and pruritus.Conclusion: It seems that topical imiquimod could be a suitableoption in the treatment of some infantile hemangioma lesions notcandidate for systemic treatment and/or other local measuressuch as laser and intra lesional steroid or when other drugs areuseless or harmful..
Seirafi Hassan; Fateh Soheil; Farnaghi Farshad; Ehsani Amir Hooshang; Noormohammadpoor Pedram
Volume 13, Issue 1 , 2010, , Pages 1-5
Abstract
Background: Although cryotherapy is still the first-line therapy for solar lentigines, due to side effects such as post-inflammatory hyperpigmentation (PIH), especially in patients with darker skin types, pigment specific lasers should be considered as initial treatment. The aim of this study was to ...
Read More
Background: Although cryotherapy is still the first-line therapy for solar lentigines, due to side effects such as post-inflammatory hyperpigmentation (PIH), especially in patients with darker skin types, pigment specific lasers should be considered as initial treatment. The aim of this study was to evaluate the efficacy and safety of cryotherapy in comparison with 595-nm pulsed dye laser (PDL) with cutaneous compression in the treatment of solar lentigines. Method: Twenty two patients (skin type II- IV) with facial or hand lentigines completed this study. Lesions of one side of the face or each hand were randomly assigned and treated with either cryotherapy or PDL. Treatments were performed with radiant exposures of 10 J/cm2, 7mm spot size and 1.5ms pulse duration with no epidermal cooling. Photographs were taken before treatment and one month later. The response rate and side effects were compared. Results: PDL was more likely to produce substantial lightening of solar lentigines than cryotherapy, especially in skin types III and IV (n=8, n=9; P0.05). PIH was only seen in the cryotherapy group. PDL group only showed minimal erythema. No purpura was observed. Conclusion: PDL with compression is superior to cryotherapy in the treatment of solar lentigines in darker skin types.
Seirafi Hassan; Farahani Farzaneh; Farnaghi Farshad; Ehsani Amirhooshang; Hashemi Pantea; Farahani Amir
Volume 11, Issue 1 , 2008, , Pages 1-6
Abstract
Background: Narrow band Ultraviolet B (NBUVB) has been used successfully for the treatment of vitiligo. Recently, topical calcipotriol has also been used as immunotherapy or as a part of combination therapies. The aim of this study was to compare the clinical efficacy and safety of NBUVB and NBUVB plus ...
Read More
Background: Narrow band Ultraviolet B (NBUVB) has been used successfully for the treatment of vitiligo. Recently, topical calcipotriol has also been used as immunotherapy or as a part of combination therapies. The aim of this study was to compare the clinical efficacy and safety of NBUVB and NBUVB plus topical calcipotriol in the treatment of generalized vitiligo.Methods: NBUVB phototherapy was given to 26 patients with generalized, symmetrical vitiligo three times weekly. Topical calcipotriol cream was only applied on the lesions located on one side of the body. Treatment was continued until cosmetically acceptable repigmentation occurred, but total cumulative dose of NBUVB did not increase from the mean of 113.4 ± 47.0 j/cm. The efficacy of treatment was evaluated by visually scoring the percentage of regimentation of the lesions at 12-session intervals by an investigator unaware of the side of calcipotriol application. Results: The mean daily dose of NBUVB was 1.4 ± 0.6 j/cm. The median number of exposure for initial regimentation was 26.5 (range 14-38) on the side of combination therapy with calcipotriol and 25.3 (range 20-40) on the other side. After 24 sessions of treatment, 14 patients (53.9%) showed minimal to moderate improvement on the calcipotriol treated side as compared to 21 patients ( 80.8 %) on the other side. After 60 sessions of treatment, 16 patients (16.5 %) showed moderate to marked regimentation on the side of combination therapy with calcipotriol as compared to 19 patients (73 %) on the other side.Conclusion: These findings indicate that concurrent use of topical calcipotriol does not enhance the efficacy of NBUVB in the treatment of vitiligo.
Mortazavi Hossein; Amirzargar Ali Akbar; Valikhani Mahin; Hallaji Zahra; Daneshpazhouh Maryam; Tabrizi Mohammad Javad Nazemi; Seirafi Hassan; Nikbin Behrouz; Khosravi Farideh; Toosi Siyavash; Chams-Davatchi Cheida
Volume 11, Issue 1 , 2008, , Pages 11-16
Abstract
Background: In addition to humoral immunity associated with anti-desmoglein antibodies, cellular immunity and mediators including cytokines are involved in the pathogenesis of pemphigus vulgaris. In this study we evaluated the level of IL-2, IFN-γ, TNF-α, IL-4, and IL-10 in the sera of patients ...
Read More
Background: In addition to humoral immunity associated with anti-desmoglein antibodies, cellular immunity and mediators including cytokines are involved in the pathogenesis of pemphigus vulgaris. In this study we evaluated the level of IL-2, IFN-γ, TNF-α, IL-4, and IL-10 in the sera of patients with pemphigus vulgaris before and after treatment.Methods: A total number of 71 new patients with pemphigus vulgaris were included in the study. The above mentioned cytokines were measured in patients with a mild disease (20 bullae or less) and a severe disease (60 bullae or more) using ELISA method before and 4 weeks after treatment with 2 mg/kg/day prednisolone and 2mg/kg/day azathioprine. We also measured IL-4 and IL-10 in 69 mildly and 70 severely affected patients only at the beginning of the study. All patients had muco-cutaneous phenotype. Patients with a mild disease had mild mucosal involvement and patients with a severe disease had moderate to severe mucosal involvement. Serum levels of IL-2 and IFN-γ were also measured in 27 normal controls.Results: In the total study population, the level of IL-2 decreased from 103.9 pg/ml to 82.79 pg/ml after treatment (p=0.05). Comparing cytokines between 2 groups (severe and mild), the level of IL-2 before treatment showed significantly lower figures in severe patients (147.27 versus 67.38, p=0.04). On the other hand, IFN-γ after treatment was significantly higher in severe patients (0.75 versus 0.42, p=0.04).Conclusion: Mean level of IL-2 is lower in severe pemphigus vulgaris patients than that of mild disease. This finding indicates that, in pemphigus vulgaris, IL-2 level negatively correlates with the severity of the disease and widespread underlying autoimmune process. The data also suggests that the level of IFN-γ directly correlates with the severity of the disease.
Farnaghi Farshad; Seirafi Hassan; Ehsani Amirhooshang; Tork Ali Naser; Yazdanian Shideh; Zarrin-nejad Neda
Volume 10, Issue 2 , 2007, , Pages 94-99
Abstract
Background and aim: Treatment of resistant warts is a common clinical problem. Immunotherapy with diphenyl cyclopropenone (DCP) as a contact sensitizer has been reported. The objective of this study was to evaluate the efficacy of DCP in refractory warts.Materials and methods: Nineteen patients with ...
Read More
Background and aim: Treatment of resistant warts is a common clinical problem. Immunotherapy with diphenyl cyclopropenone (DCP) as a contact sensitizer has been reported. The objective of this study was to evaluate the efficacy of DCP in refractory warts.Materials and methods: Nineteen patients with refractory warts referred to Razi Hospital in 2004 who had not responded to at least 2 treatment modalities, were sensitized with 2% DCP in acetone.Then treatment was started with application of 1% DCP on plantar warts and 0.2% on other locations.Results: Two patients were not sensitized even after 3 attempts. Three other patients discontinuedtreatment due to side effects (severe eczema and pruritus). Six male and 8 female patients completed the trial, among them,10 (71.5%) showed complete clearance of warts. Side effects reported were: local pruritus (21%), distant eczema (10.5%), local blister (26.3%). The patients received a mean of 5 treatment sessions.Conclusion: Topical immunotherapy with DCP is an effective treatment for refractory warts. Due to high efficacy, no scarring, and being a painless procedure it can be considered as a first line treatment of refractory warts.